Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Cuts 25 Percent of Workforce

SAN FRANCISCO, Jan. 22 - Lynx Therapeutics said today that it was laying off 25 percent of its staff.

 

The cutting of 30 people, primarily research and development staff based in Heidelberg, Germany, and workers in the proteomics group in California, brings the total company headcount to 90 people, according to Lynx.

 

In April Lynx laid off 44 employees.

 

This round of layoffs marks the discontinuation of the company's proteomics development efforts, including investment in its Protein Profiler, Lynx CEO Kevin Corcoran said in a statement.

 

"Our business strategy will focus on MPSS, our product that currently generates revenues for us primarily through genomics discovery services for our customers," said Corcoran.

 

Last week, Lynx received additional notice by Nasdaq that the company was in danger of being delisted from the stock exchange.

 

 

 

 

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.